Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
06/2010
06/09/2010CN101422446B Vitamin K micro-capsule preparation method
06/09/2010CN101328470B Rhamnose bacterium lacticum grx10 having cholesterol lowering and antibacterial functionsand use thereof
06/09/2010CN101250133B Novel method for synthesizing (+/-)p-fluoro-2-(2-methyl-propionyl)-4-oxygen-N,3-diphenyl-benzenebutanamide and intermediate therein
06/09/2010CN101181491B Method for preparing jiang-zhi-yin capsule
06/09/2010CN101167763B Monascus and total ginkgolide composition for preventing and treating cardiovascular and cerebrovascular diseases
06/09/2010CN101120786B Nutritive food for diabetic in middle and old age and manufacturing method thereof
06/09/2010CN101095769B Health-care food for reducing blood lipid and method for preparing the same
06/09/2010CN101010076B Immune function-improving agent
06/08/2010US7732617 Tocopherol derivatives and uses thereof
06/08/2010US7732596 2-( beta -D-Glucopyranosyl)-4-(2-phenylethyl)benzo[b]thiophene; prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity
06/08/2010US7732492 tablet comprising disintegrant such as carmellose, sodium carboxymethyl starch, croscarmellose sodium, crospovidone, partly pregelatinized starch and low-substituted hydroxypropyl cellulose
06/08/2010US7732488 Marine oil derived ethyl ester of eicosapentaenoic acid and docosahexaenoic acid, with specified reduced levels of brominated flame retardants; not a health supplement; treat hypertriglyceridaemia
06/08/2010US7732480 Bicyclic compounds as modulators of androgen receptor function and method
06/08/2010US7732471 e.g. 2-Methyl-6-[3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)propoxymethyl]benzoic acid; peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonists/antagonists; insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistance; atherosclerosis
06/08/2010US7732456 such as 4-benzyloxy-1-{4-[2-(dimethylamino)ethoxy]phenyl}-1H-pyridin-2-one, that as antagonists to melanin concentrating hormone receptors, used for treating cardiovascular, nervous system, metabolic, reproductive system, respiratory system and gatrointestinal disorders
06/08/2010US7732455 Adenosine A2B receptor antagonists; asthma, allergies, allergic diseases or an autoimmune disease, diarrheal diseases, insulin resistance, diabetes, cancer, ischemia, reperfusion injuries, retinopathy; e.g. 1,3-Dipropyl-8-(6-chloro-3-pyridyl)xanthine
06/08/2010US7732447 such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases
06/08/2010US7732442 N-[5-bromo-3-({3-[2-(dimethylamino)ethoxy]-4-methoxybenzyl}oxy)pyridin-2-yl]-4-methylbenzenesulfonamide, used for prevention and/or treatment of infections, inflammatory and/or allergic diseases
06/08/2010US7732413 1,4-Diphenyl-3-substituted azetidin-2-ones; can be metabolized in vivo to form a sterol and/or stanol absorption inhibitor and a sterol biosynthesis inhibitor for treatment of atherosclerosis, hypercholesterolemia, or sitosterolemia
06/08/2010US7732146 Method for screening an agent that modulates activity of macrophage migration inhibitory factor
06/08/2010US7731983 Method and composition for the treatment of scars
06/08/2010US7731961 Methods of increasing muscle mass or muscle strength using antibody inhibitors of GDF-8
06/08/2010CA2440553C 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
06/08/2010CA2440213C Method for improving the well-being of poultry by in-ovo injection of carnitine
06/08/2010CA2439241C Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
06/08/2010CA2431983C Novel 1,2-diphenylazetidinones, processes for their preparation, medicaments comprising these compounds and their use for treating impaired lipid metabolism
06/08/2010CA2416442C Substituted 5-alkynyl pyrimidines having neurotrophic activity
06/08/2010CA2389300C 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
06/08/2010CA2379210C Composition for enteral nutrition containing fibre
06/08/2010CA2369300C Water-soluble compositions of bioactive lipophilic compounds
06/08/2010CA2275060C Novel triglyceride and composition comprising the same
06/03/2010WO2010062863A2 Compositions containing satiogens and methods of use
06/03/2010WO2010062861A2 Bile acid recycling inhibitors for treatment of obesity and diabetes
06/03/2010WO2010062824A2 Enhanced bioactive formulations of resveratrol
06/03/2010WO2010062681A2 Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism
06/03/2010WO2010061971A1 Pyridine-3-carboxyamide derivative
06/03/2010WO2010061921A1 Method for stabilizing l-ascorbic acid, liquid extraction preparation, solid extract, and semi-fluid extract
06/03/2010WO2010061880A1 Vesicle preparation
06/03/2010WO2010061877A1 Mineral absorption improver, and method for improving absorption of minerals
06/03/2010WO2010061787A1 Beauveriolide having acat-2 inhibitory activity
06/03/2010WO2010061180A1 Quinoline derivatives as p13 kinase inhibitors
06/03/2010WO2010061074A1 Indole derivatives, method for preparing same and pharmaceutical compositions containing same
06/03/2010WO2010060952A1 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
06/03/2010WO2010060472A1 Imidazopyridazine derivatives acting as orexin antagonists
06/03/2010WO2010060471A1 Piperidine derivatives useful as orexin receptor antagonists
06/03/2010WO2010060470A1 Piperidine derivatives useful as orexin receptor antagonists
06/03/2010WO2010060387A1 The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof
06/03/2010WO2010027498A3 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
06/03/2010WO2010022262A3 Methods for treating type i diabetes with leptin and leptin agonists
06/03/2010WO2010019276A3 Method and formulation for treating adverse biological conditions
06/03/2010WO2010015657A3 Alkoxypyrazoles and the process for their preparation
06/03/2010WO2010015656A3 Alkoxypyrazoles and the process for their preparation
06/03/2010WO2010009210A3 Acetylsalicyclic acid derivatives useful to treat metabolic syndromes
06/03/2010WO2009109654A8 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
06/03/2010US20100137696 Medical device with reservoir-based sensors
06/03/2010US20100137444 Ketone compounds and compositions for cholesterol management and related uses
06/03/2010US20100137422 Novel phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome
06/03/2010US20100137417 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
06/03/2010US20100137402 N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application
06/03/2010US20100137401 2-methylprop anamides and their use as pharmaceuticals
06/03/2010US20100137397 Chemical Compounds
06/03/2010US20100137393 Prediction and prophylactic treatment of type 1 diabetes
06/03/2010US20100137391 Histamine H3 Agonist for use as Therapeutic Agent for a Lipid/Glucose Metabolic Disorder
06/03/2010US20100137387 Beta-keto-amide derivatives useful as ion channel modulators
06/03/2010US20100137381 Acetamide derivatives as potassium channel modulators
06/03/2010US20100137377 Novel compounds
06/03/2010US20100137364 6-Aminoisoquinoline Compounds
06/03/2010US20100137360 Trpv1 antagonists
06/03/2010US20100137359 Caspase inhibitors and uses thereof
06/03/2010US20100137356 Azaindole-indole coupled derivatives, preparation methods and uses thereof
06/03/2010US20100137321 IMIDAZO[1,2-a]AZINES AND THEIR USE AS PHARMACEUTICALS
06/03/2010US20100137319 Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
06/03/2010US20100137317 1,2-Disubstituted Heterocyclic Compounds
06/03/2010US20100137307 Novel 1,2,3,4,-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced terein and has glucocorticoid receptor-binding activity
06/03/2010US20100137301 Substituted Indolealkanoic Acids
06/03/2010US20100137293 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
06/03/2010US20100137291 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
06/03/2010US20100137289 Methods and Compositions for Ameliorating Thiazide Induced Hyperlipidemia
06/03/2010US20100137288 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
06/03/2010US20100137280 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
06/03/2010US20100137273 Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
06/03/2010US20100137267 Formulations for treatment of adipose tissue, cutaneous tissue and disorders, and muscular tissue
06/03/2010US20100137266 Treatment of insulin resistance and disorders associated therewith
06/03/2010US20100137244 Preparation and utility of hmg-coa reductase inhibitors
06/03/2010US20100137234 10-substituted macrolide antibiotics
06/03/2010US20100137202 Compositions for reprogramming a cell and uses therefor
06/03/2010US20100137198 Pharmaceutical composition for topical application
06/03/2010US20100137194 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism
06/03/2010US20100136623 Mutations in ion channels
06/03/2010US20100136575 B7-related nucleic acids and polypeptides useful for immunomodulation
06/03/2010US20100136522 Endogenous retroviruses up-regulated in prostate cancer
06/03/2010US20100136150 Pharmaceutical composition for treating diabetes and its process for preparation
06/03/2010US20100136145 Formulations containing cynara scolymus and phaseolus vulgaris extracts which are useful in the treatment of obesity
06/03/2010US20100136133 Nutritive compositions and methods of using same
06/03/2010US20100136127 Solid preparation comprising alogliptin and metformin hydrochloride
06/03/2010US20100136126 Composition and microsphere for controlled-release of exendin, and method of preparing the same
06/03/2010US20100136122 Oral Preparation Comprising Pioglitazone
06/03/2010US20100136118 Calcium absorption enhancer
06/03/2010US20100136030 Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
06/03/2010US20100136020 Uses of il-174 antagonists for inhibiting a th2 immune response
1 ... 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 ... 1298